Update from ESMO Virtual Plenary: TROPION-Breast01 trial скачать в хорошем качестве

Update from ESMO Virtual Plenary: TROPION-Breast01 trial

Prof. François-Clément Bidard and Dr Barbara Pistilli share expert insights on the latest TROPION-Breast01 update, presenting the final OS results from the ESMO Virtual Plenary 2025. This study evaluates datopotamab deruxtecan (Dato-DXd) versus chemotherapy in previously treated, inoperable or metastatic HR+/HER2– breast cancer. In this video, the experts explore: Mechanism of action of Dato-DXd TROPION-Breast01 PFS results and safety outcomes Final overall survival results and their clinical implications The future outlook for Dato-DXd Clinical takeaways TROPION-Breast01 final OS results did not reach statistical significance; however, subsequent ADC treatment may have influenced survival outcomes The dual primary endpoint of PFS demonstrates a statistically significant and clinically meaningful improvement with Dato-DXd compared with chemotherapy Secondary efficacy and PRO endpoints continued to show a benefit for Dato-DXd in this final analysis This educational programme is supported by an Independent Educational Grant from AstraZeneca February 2025